Industry News
Biotechnology Industry News

Future shaky at Solid Bio as it shaves off 35% of workforce, chief operating officer plans exit
Future shaky at Solid Bio as it shaves off 35% of workforce, chief operating officer plans exit gmasson Wed, 04/27/2022 - 10:47
BridgeBio strategy head departs amid company’s second round of layoffs this year
BridgeBio strategy head departs amid company’s second round of layoffs this year mbayer Wed, 04/27/2022 - 10:39
BridgeBio strategy head departs amid company’s 2nd round of layoffs this year
BridgeBio strategy head departs amid company's 2nd round of layoffs this year mbayer Wed, 04/27/2022 - 10:39
2 become 1: Caladrius and Cend merge into tumor-focused Lisata Therapeutics
2 become 1: Caladrius and Cend merge into tumor-focused Lisata Therapeutics jwaldron Wed, 04/27/2022 - 09:41
Cytovia inks SPAC merger to get natural killer cells prospects into the clinic
Cytovia inks SPAC merger to get natural killer cells prospects into the clinic ntaylor Wed, 04/27/2022 - 09:21
Spying synthetic lethal promise, Pfizer bets $25M on Zentalis, will support cancer trials
Spying synthetic lethal promise, Pfizer bets $25M on Zentalis, will support cancer trials ntaylor Wed, 04/27/2022 - 07:46
Zolgensma for dementia? AviadoBio gains orphan tag for one-dose gene therapy
Zolgensma for dementia? AviadoBio gains orphan tag for one-dose gene therapy jwaldron Wed, 04/27/2022 - 07:12
Amgen opts to DARP-out after seeing early data from $50M Molecular Partners collab
Amgen opts to DARP-out after seeing early data from $50M Molecular Partners collab aarmstrong Tue, 04/26/2022 - 16:45
UPDATE: Amgen opts to DARP-out after seeing early data from $550M Molecular Partners biobucks collab
UPDATE: Amgen opts to DARP-out after seeing early data from $550M Molecular Partners biobucks collab aarmstrong Tue, 04/26/2022 - 16:45
Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder
Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder gmasson Tue, 04/26/2022 - 11:03
Pfizer-Valneva’s Lyme disease vaccine performs even better in children
Pfizer-Valneva's Lyme disease vaccine performs even better in children aarmstrong Tue, 04/26/2022 - 10:27
After phase 2 flop, BerGenBio posts new data on COVID-19 prospect
After phase 2 flop, BerGenBio posts new data on COVID-19 prospect ntaylor Tue, 04/26/2022 - 08:25
Not IDEAL: Protagonist sinks as high dose of oral Entyvio rival fails in ulcerative colitis
Not IDEAL: Protagonist sinks as high dose of oral Entyvio rival fails in ulcerative colitis ntaylor Tue, 04/26/2022 - 05:43
Ready to eat: Investors fork out $76M for Pheast’s cancer therapies
Ready to eat: Investors fork out $76M for Pheast's cancer therapies gmasson Mon, 04/25/2022 - 18:59
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends aarmstrong Mon, 04/25/2022 - 17:22
UPDATE: Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
UPDATE: Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends aarmstrong Mon, 04/25/2022 - 17:22
Trevena’s COVID-19 drug trial halted for inferiority, as NIH continues ACTIV house cleaning
Trevena's COVID-19 drug trial halted for inferiority, as NIH continues ACTIV house cleaning mbayer Mon, 04/25/2022 - 15:53
UPDATE: Trevena’s COVID-19 drug trial halted for inferiority as NIH continues ACTIV house cleaning
UPDATE: Trevena's COVID-19 drug trial halted for inferiority as NIH continues ACTIV house cleaning mbayer Mon, 04/25/2022 - 15:53
Progress with Promise with Ibex® Design’s 11-month DNA to IND guarantee
Progress with Promise with Ibex® Design’s 11-month DNA to IND guarantee ncavazza Mon, 04/25/2022 - 15:26
Another setback for Axsome as migraine med expected to get a no from FDA
Another setback for Axsome as migraine med expected to get a no from FDA mbayer Mon, 04/25/2022 - 13:33

